INTRACORONARY ADMINISTRATION OF TENECTEPLASE VERSUS ABCIXIMAB AS ADJUNCTIVE TREATMENT DURING PRIMARY ANGIOPLASTY IN ACUTE MYOCARDIAL INFARCTION OF ANTERIOR LOCATIO
- Conditions
- ACUTE MYOCARDIAL INFARCTIONMedDRA version: 14.1Level: LLTClassification code 10000894Term: Acute myocardial infarction, of anterolateral wall, initial episode of careSystem Organ Class: 10007541 - Cardiac disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
- Registration Number
- EUCTR2010-022725-16-ES
- Lead Sponsor
- FRANCISCO JOSE MORALES PONCE
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
-ST-segment elevation acute myocardial infarction (STEMI) < 12 hours, with ST elevation = 2mm in precordial leads in ECG (compatible with STEMI of anterior wall), or new-onset left-bundle branch block
-Performance of urgent coronary angiography with evidence of a coronary flow limitant lesion in left-descending coronary artery (TIMI 0-2 flow) and intention to perform primary angioplasty
-Written informed consent for study
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 25
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 35
-Cardiogenic shock
-Previous myocardial infarction (chronic)
-Sever active bleeding
-Contraindications for fibrinolytics or abciximab
-Contraindicaction for cardiac magnetic resonance with contrast (angio-MNR), such as metallic intracraneal implants, pacemakers, moderate-to-severe renal insufficiency)
-Age under 18
-Pregnancy
-Severe hepatic insufficiency
-Severe diseases which can limit life expectancy under 12 months
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method